Nitazoxanide for the treatment of Clostridium difficile colitis

Clinical Infectious Diseases

Volumn 43, Issue 4, 2006, Pages 421-427

  Musher, Daniel M ^a,b   Logan, Nancy ^a   Hamill, Richard J ^a,b   DuPont, Herbert L ^b,c   Lentnek, Arnold ^d   Gupta, Arvind ^e,f   Rossignol, Jean Francois ^g  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d WellStar Kennestone Hospital   (United States)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

^f LEHIGH VALLEY HOSPITAL   (United States)

^g Romark Institute for Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; NITAZOXANIDE; TIZOXANIDE; VANCOMYCIN;

AGED; ANAEROBIC METABOLISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOSPORIDIUM; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EUKARYOTE; FEMALE; GIARDIA; HUMAN; IN VITRO STUDY; INCIDENCE; INFESTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; METRONIDAZOLE; THIAZOLES;

EID: 33746626011     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/506351     Document Type: Article

References (28)

1. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004; 189:1585-9.
2. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
3. McDonald LC, Owings M, Jernigan DB. Increasing rates of Clostridium difficile infection among patients discharged from U.S. short stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:111-222.
4. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.
5. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
6. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26:273-80.
7. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84.
8. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
9. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005; 40:265-72.
10. Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile. N Engl J Med 2006; 354:1199-203.
11. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk-four states. MMWR Morb Mortal Wkly Rep 2005; 54:1201-5.
12. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549-57.
13. Cherry RD, Portnoy D, Jabbari M, Daly DS, Kinnear DG, Goresky CA. Metronidazole: an alternate therapy for antibiotic-associated colitis. Gastroenterology 1982; 82:849-51.
14. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043-6.
15. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92:739-50.
16. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 1998; 55:1407-11.
17. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
18. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46:1647-50.
19. White CA Jr. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther 2004; 2:43-9.
20. Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005; 40:1173-80.
21. Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996; 40:2266-70.
22. Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JF. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000; 38:387-94.
23. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331-51.
24. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17:873-90.
25. Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am J Gastroenterol 1998; 93:1873-6.
26. Barbut F, Decre D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43:2607-11.
27. Freeman J, Stott J, Baines SD, Fawley WN, Wilcox MH. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005; 56:988-9.
28. Johnson S, Sanchez JL, Gerding DN. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000; 31:625-6.